The RespirERA Institute strengthens its research capabilities with the acquisition of the NovaSeq X

The RespirERA Institute is continuing to develop its genomics platform with the acquisition of the NovaSeq X, one of the most powerful next-generation sequencers currently available. This acquisition marks an important step in accelerating research on respiratory diseases and opens up short- and medium-term perspectives for improving patient care.

A new capacity to explore respiratory diseases

The NovaSeq X is a very high-throughput sequencing technology, designed to rapidly read a large number of tissue or liquid samples with very high sensitivity. Thanks to this new platform, the teams at the RespirERA Institute will be able to analyse a much larger number of samples with excellent sequencing depth, particularly from circulating nucleic acids collected from blood samples, while generating massive amounts of highly reliable data.

This increased capacity will make it possible to conduct large-scale studies on diseases such as lung cancer, as well as COPD and fibrosing lung diseases.

The implementation of analytical techniques for the detection of residual disease, particularly in perioperative settings and in the monitoring of patients with lung cancer, will be proposed rapidly.

Finally, the capabilities of this sequencer also open the way to multi-omics studies and the analysis of the entire genome of lung tumours, with particular interest for patients who have never smoked.

Accelerating the research of tomorrow

The acquisition of the NovaSeq X opens up new perspectives for the work carried out by the RespirERA Institute. This technology will notably support the development of approaches combining genomics, methylomics and proteomics, the study of disease mechanisms at the cellular level, and the identification of new biomarkers — biological indicators useful for diagnosis, therapeutic decision-making or patient monitoring.

By strengthening its ability to generate and analyse high-quality biological data at scale, the RespirERA Institute is equipping itself with a strategic tool to advance respiratory health research, integrate multimodal approaches and support the emergence of increasingly personalised medicine.